---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-24-000016"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:27:34.786590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q1 adjusted EPS $2.31 (-6.1% YoY); raises 2024 guidance; CEO succession

## Summary
- Q1 revenue $12.31B (+0.7% reported, +1.6% operational); GAAP EPS $0.77, adjusted EPS $2.31.
- Immunology revenue $5.371B (-3.9%) on Humira erosion; Skyrizi +47.6%, Rinvoq +59.3%.
- Oncology +9% to $1.543B; Neuroscience +15.9% to $1.965B; Aesthetics -4% to $1.249B.
- Raises 2024 adjusted EPS guidance to $11.13-$11.33 from $10.97-$11.17; includes $0.08 IPR&D impact.
- CEO succession: Robert Michael to become CEO July 1; Richard Gonzalez becomes executive chairman.

## SEC filing metadata
- accession: 0001551152-24-000016
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/0001551152-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/abbv-20240426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-24-000016
- JSON: https://secwatch.observer/filing/0001551152-24-000016.json
- Plain text: https://secwatch.observer/filing/0001551152-24-000016.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported the first quarter ended March 31, 2024 results: revenue $12.310 Billion, EPS Diluted EPS of $0.77 on a GAAP Basis. Guidance raised.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $12.310 Billion
  - EPS: Diluted EPS of $0.77 on a GAAP Basis
  - Guidance: raised
  - Result: reported results
  source text: Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense • Delivers First-Quarter Net Revenues of $12.310 Billion, an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational Basis • First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.371 Billion, a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/0001551152-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.